Paris, France

Maria Loustau

USPTO Granted Patents = 7 

Average Co-Inventor Count = 4.4

ph-index = 3

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 2021-2025

Loading Chart...
7 patents (USPTO):Explore Patents

Title: Maria Loustau: Innovator in Immunology

Introduction

Maria Loustau is a prominent inventor based in Paris, France. She has made significant contributions to the field of immunology, particularly in the development of chimeric antigen receptors and antibodies targeting human leukocyte antigen-G (HLA-G). With a total of 7 patents to her name, Loustau is recognized for her innovative approaches to addressing complex medical challenges.

Latest Patents

Among her latest patents is the invention of chimeric antigen receptors against multiple HLA-G isoforms. This invention focuses on CARs that are specific for HLA-G β2M-free or β2M-associated immunosuppressive isoforms. Another notable patent involves anti-HLA-G specific antibodies, which are directed against the HLA-G protein and raised against an immunogenic peptide derived from the α3 domain of the HLA-G protein. These advancements hold promise for improving therapeutic strategies in immunology.

Career Highlights

Maria Loustau has established herself as a leading figure in her field through her innovative research and patent contributions. Her work has not only advanced scientific understanding but also paved the way for potential clinical applications. She is currently associated with Invectys SA, a company dedicated to developing innovative immunotherapies.

Collaborations

Throughout her career, Loustau has collaborated with notable colleagues, including Pierre Langlade Demoyen and Julien Caumartin. These partnerships have further enriched her research and contributed to the success of her projects.

Conclusion

Maria Loustau's contributions to immunology through her patents and collaborations highlight her role as a key innovator in the field. Her work continues to inspire advancements in medical science and therapeutic development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…